NYSE:NUS - Nu Skin Enterprises Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $51.63 +0.10 (+0.19 %) (As of 05/21/2019 04:00 PM ET)Previous Close$51.53Today's Range$50.96 - $52.2652-Week Range$44.36 - $88.68Volume505,500 shsAverage Volume723,228 shsMarket Capitalization$2.86 billionP/E Ratio14.67Dividend Yield2.87%Beta0.67 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates walk-in centers and pick-up locations; and retail stores and service centers in Mainland China. The company sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah. Receive NUS News and Ratings via Email Sign-up to receive the latest news and ratings for NUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Drugs, proprietaries, & sundries Sub-IndustryPersonal Products SectorConsumer Staples Current SymbolNYSE:NUS Previous Symbol CUSIP67018T10 CIK1021561 Webhttp://www.nuskinenterprises.com/ Phone801-345-1000Debt Debt-to-Equity Ratio0.44 Current Ratio1.86 Quick Ratio1.10Price-To-Earnings Trailing P/E Ratio14.67 Forward P/E Ratio13.17 P/E Growth1.17 Sales & Book Value Annual Sales$2.68 billion Price / Sales1.07 Cash Flow$5.1373 per share Price / Cash Flow10.05 Book Value$14.62 per share Price / Book3.53Profitability EPS (Most Recent Fiscal Year)$3.52 Net Income$121.88 million Net Margins4.82% Return on Equity26.81% Return on Assets12.47%Miscellaneous Employees4,900 Outstanding Shares55,486,000Market Cap$2.86 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Nu Skin Enterprises (NYSE:NUS) Frequently Asked Questions What is Nu Skin Enterprises' stock symbol? Nu Skin Enterprises trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUS." How often does Nu Skin Enterprises pay dividends? What is the dividend yield for Nu Skin Enterprises? Nu Skin Enterprises announced a quarterly dividend on Wednesday, May 1st. Stockholders of record on Friday, May 31st will be paid a dividend of $0.37 per share on Wednesday, June 12th. This represents a $1.48 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, May 30th. View Nu Skin Enterprises' Dividend History. How were Nu Skin Enterprises' earnings last quarter? Nu Skin Enterprises, Inc. (NYSE:NUS) announced its quarterly earnings data on Tuesday, April, 30th. The company reported $0.77 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.71 by $0.06. The firm earned $623.60 million during the quarter, compared to analysts' expectations of $615.98 million. Nu Skin Enterprises had a net margin of 4.82% and a return on equity of 26.81%. The company's revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.79 earnings per share. View Nu Skin Enterprises' Earnings History. When is Nu Skin Enterprises' next earnings date? Nu Skin Enterprises is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Nu Skin Enterprises. What guidance has Nu Skin Enterprises issued on next quarter's earnings? Nu Skin Enterprises updated its FY19 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of $3.80-4.05 for the period, compared to the Thomson Reuters consensus estimate of $3.89. The company issued revenue guidance of $2.76-2.81 billion, compared to the consensus revenue estimate of $2.77 billion.Nu Skin Enterprises also updated its Q2 guidance to $0.91-0.98 EPS. What price target have analysts set for NUS? 8 equities research analysts have issued 12 month target prices for Nu Skin Enterprises' stock. Their predictions range from $43.00 to $92.00. On average, they anticipate Nu Skin Enterprises' share price to reach $73.5714 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for Nu Skin Enterprises. What is the consensus analysts' recommendation for Nu Skin Enterprises? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nu Skin Enterprises in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nu Skin Enterprises. What are Wall Street analysts saying about Nu Skin Enterprises stock? Here are some recent quotes from research analysts about Nu Skin Enterprises stock: 1. According to Zacks Investment Research, "Nu Skin, which has outdone the industry in the past month, has been steadily gaining from solid performance across most regional units and sustained growth in customer count. These upsides and enhanced margins fueled first-quarter 2019 results, wherein top and bottom lines grew year over year and surpassed estimates. Further, the company’s focus on expanding global beauty device systems and optimizing the Velocity program bodes well. This is reflected in management’s outlook for 2019. However, the company issued a soft view for the second quarter, which is likely to be hurt by tough year-over-year comparisons related to LumiSpa. Moreover, currency headwinds are expected to persist, and hurt sales growth by 4-5% and 2-3% in the second quarter and 2019, respectively. Competition from cheaper alternatives is certainly a threat as well." (5/3/2019) 2. Pivotal Research analysts commented, "We do expect share repurchase to accelerate and contribute meaningfully to 2019 and 2020. In 2018 diluted shares rose 2.3% compared to -2% in 2017; and -4.9% in 2016. NUS loves to shrink its share count. We think 2019 might be bigger than usual which is not in the guidance. We find the multi-year prospects for NUS shares to be excellent. Top line growth and expanding EBIT margins, accelerating share repurchases and a tax rate that may drift lower sets the stage for double-digit gains in EPS for many years. Management is excellent and improving the speed to market and technology of the business. It really is a near-perfect setup." (2/13/2019) Has Nu Skin Enterprises been receiving favorable news coverage? News headlines about NUS stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nu Skin Enterprises earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Nu Skin Enterprises' key competitors? Some companies that are related to Nu Skin Enterprises include Herbalife Nutrition (HLF), PetIQ (PETQ), Trxade Group (TRXD), biOasis Technologies (BIOAF), Aceto (ACET) and Medizone International (MZEI). What other stocks do shareholders of Nu Skin Enterprises own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nu Skin Enterprises investors own include Alibaba Group (BABA), General Electric (GE), Marathon Petroleum (MPC), Herbalife Nutrition (HLF), Baidu (BIDU), Alphabet (GOOG), Netflix (NFLX), Mastercard (MA), Tesla (TSLA) and Booking (BKNG). Who are Nu Skin Enterprises' key executives? Nu Skin Enterprises' management team includes the folowing people: Mr. Steven J. Lund, Exec. Chairman (Age 66)Mr. Ritch N. Wood, CEO & Director (Age 53)Mr. Ryan S. Napierski, Pres (Age 45)Mr. Mark H. Lawrence, Exec. VP & CFO (Age 49)Dr. Joseph Y. Chang, Exec. VP of Product Devel. & Chief Scientific Officer (Age 66) Who are Nu Skin Enterprises' major shareholders? Nu Skin Enterprises' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.54%), Wellington Management Group LLP (3.65%), AJO LP (2.55%), William Blair Investment Management LLC (2.29%), Renaissance Technologies LLC (2.26%) and Dimensional Fund Advisors LP (2.14%). Company insiders that own Nu Skin Enterprises stock include D Matthew Dorny, Daniel W Campbell, Edwina D Woodbury, Joseph Y Chang, Mark H Lawrence, Neil H Offen, Pisano R Thomas, Ryan S Napierski and Steven Lund. View Institutional Ownership Trends for Nu Skin Enterprises. Which major investors are selling Nu Skin Enterprises stock? NUS stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., MERIAN GLOBAL INVESTORS UK Ltd, AQR Capital Management LLC, OppenheimerFunds Inc., First Trust Advisors LP, Robeco Institutional Asset Management B.V., Bank of Montreal Can and AJO LP. Company insiders that have sold Nu Skin Enterprises company stock in the last year include D Matthew Dorny, Edwina D Woodbury, Joseph Y Chang, Neil H Offen and Ryan S Napierski. View Insider Buying and Selling for Nu Skin Enterprises. Which major investors are buying Nu Skin Enterprises stock? NUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Morgan Stanley, Delek Group Ltd., Federated Investors Inc. PA, Voya Investment Management LLC, Acadian Asset Management LLC and Prescott Group Capital Management L.L.C.. View Insider Buying and Selling for Nu Skin Enterprises. How do I buy shares of Nu Skin Enterprises? Shares of NUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nu Skin Enterprises' stock price today? One share of NUS stock can currently be purchased for approximately $51.63. How big of a company is Nu Skin Enterprises? Nu Skin Enterprises has a market capitalization of $2.86 billion and generates $2.68 billion in revenue each year. The company earns $121.88 million in net income (profit) each year or $3.52 on an earnings per share basis. Nu Skin Enterprises employs 4,900 workers across the globe. What is Nu Skin Enterprises' official website? The official website for Nu Skin Enterprises is http://www.nuskinenterprises.com/. How can I contact Nu Skin Enterprises? Nu Skin Enterprises' mailing address is 75 WEST CENTER ST, PROVO UT, 84601. The company can be reached via phone at 801-345-1000 or via email at [email protected] MarketBeat Community Rating for Nu Skin Enterprises (NYSE NUS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 435 (Vote Outperform)Underperform Votes: 397 (Vote Underperform)Total Votes: 832MarketBeat's community ratings are surveys of what our community members think about Nu Skin Enterprises and other stocks. Vote "Outperform" if you believe NUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.